SFM
ITOS

Sphera Funds Management’s iTeos Therapeutics ITOS Stock Holding History

Sphera Funds Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-250,000
Closed -$6.17M – 121
2020
Q3 		$6.17M Buy
+250,000
New +$6.72M 0.61% 48

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sphera Funds Management's ITOS Position: Q4 2020 in Review

Sphera Funds Management sold out of iTeos Therapeutics (ITOS) in Q4 2020, closing a stake of 250,000 shares — an estimated $6.17M sold.

Sphera Funds Management first reported a position in ITOS in Q3 2020 and held it in 1 quarter. The position peaked at $6.17M in Q3 2020. 71 funds tracked by Wall St. Rank hold ITOS as of Q4 2020.

  • Sphera Funds Management reported no remaining iTeos Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Sphera Funds Management sold 250,000 iTeos Therapeutics shares in Q4 2020, an estimated $6.17M.
  • Sphera Funds Management first reported a position in iTeos Therapeutics in Q3 2020 and held it in 1 quarter.
  • Sphera Funds Management's iTeos Therapeutics position peaked at $6.17M in Q3 2020.
  • 71 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2020.

Based on Sphera Funds Management's 13F filing for Q4 2020, filed 16 Feb 2021.